Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

By J. Chiasson, R. Josse, R. Gomis, M. Hanefeld, A. Karasik, Markku Laakso, Theodora S Temelkova-Kurktschiev. Journal of the American Medical Association (JAMA), 2003

1,728 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/94864cf0506d4647f9a4f7f83b1217afa3a0ebe5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

Citations in the corpus

The metabolic syndrome. (2008, result): “This trial also showed that acarbose treatment was in fact associated with reduced CVD and hypertension (603).”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, background): “tion, new angina, revascularization, cardiovascular death, congestive heart failure, cerebrovascular events, and peripheral vascular disease) by 49% in subjects with impaired glucose tolerance in the STOP-Noninsulin Dependent Diabetes (NIDDM) trial.(81) However,”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “Acarbose has demonstrated to have beneficial effects by reducing the risk of cardiovascular disease and slowing the progression to diabetes in patients with impaired glucose tolerance [93,94] .”
Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). (2015, neutral): “In the acarbose trial described above, risk of CVD was also reduced by 49% [32].”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Clinical trials have shown CVD benefit in patients with impaired glucose tolerance and diabetes (64,114).”
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. (2004, result): “The first study to investigate the relationship between lowering postprandial blood glucose by acarbose therapy and the development of CV events has been the STOPNIDDM trial in IGT patients.(24) The study reported a significant reduction using acarbose in the development of CV events of any type, of”